Author:
Yang Chan,Yang Qiangfei,Xie Ziyan,Peng Xi,Liu Hanyu,Xie Chunguang
Abstract
Abstract
Purpose
There have been limited studies examining the prospective association between the Systemic Immune-Inflammation Index (SII), a novel inflammatory marker, and mortality among individuals with diabetes in the United States.
Methods
We utilized data from the National Health and Nutrition Examination Survey (NHANES), a representative sample of US adults, linked with information from the National Death Index.
Results
Our study included 8697 individuals from NHANES spanning the years 1999 to 2018. SII was calculated by dividing the platelet count by the neutrophil count and then dividing that result by the lymphocyte count. We employed multivariable Cox proportional hazards regression analysis to investigate the associations between SII levels and all-cause as well as cause-specific mortality, while adjusting for potential confounding factors. SII levels were categorized into quartiles based on the study population distribution. Over a median follow-up period of 94.8 months (with a maximum of 249 months), we observed a total of 2465 all-cause deaths, 853 deaths from cardiovascular causes, 424 deaths from cancer, and 88 deaths related to chronic kidney disease. After adjusting for multiple variables, higher SII levels were significantly and non-linearly associated with an increased risk of all-cause mortality in Quartile 4 (HR 1.74, 95% CI 1.15–2.63, P for trend = 0.043) when Quartile 1 was used as the reference group. Additionally, we identified a linear association between SII and cardiovascular mortality, with a 70% higher risk of cardiovascular mortality in Quartile 4 (HR 1.70, 95% CI 1.18–3.30, P for trend = 0.041) compared to Quartile 1.
Conclusion
Our findings indicate that SII is significantly associated with an elevated risk of all-cause and cardiovascular mortality in US adults with diabetes.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference31 articles.
1. H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova, B.B. Duncan et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pr. 183, 109119 (2022)
2. J.C.N. Chan, L.-L. Lim, N.J. Wareham, J.E. Shaw, T.J. Orchard, P. Zhang et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 396, 2019–82 (2021)
3. W. Ebstein, Zur therapie des Diabetes mellitus, insbesondereüber die Anwendung des salicylsauren Natron bei demselben. Berliner Klinische Wochenschrift. (1876)
4. T.V. Rohm, D.T. Meier, J.M. Olefsky, M.Y. Donath, Inflammation in obesity, diabetes, and related disorders. Immunity 55, 31–55 (2022)
5. S.E. Shoelson, J. Lee, A.B. Goldfine, Inflammation and insulin resistance. J. Clin. Invest. 116, 1793–1801 (2006)